Daiichi Sankyo Will Focus On Six Therapeutic Areas
This article was originally published in The Pink Sheet Daily
Executive Summary
Merger will allow the partners to increase R&D in cardiovascular, antibacterial, glucose metabolic, bone disorder, immune disorder and anti-allergy categories. As a single entity, Daiichi and Sankyo expect to increase their combined 2,200-person global sales force.